Home › Endometrial Cancer › Massachusetts › Boston
Endometrial Cancer clinical trials in Boston, MA
51 studies for Endometrial Cancer are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
RecruitingPhase 1
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
RecruitingPhase 1
- Mass General Brigham Cancer Institute, Boston
- Dana Farber Cancer Institute, Boston
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
RecruitingPhase 1
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RecruitingPhase 2
- Massachusetts General Hospital Cancer Center, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
RecruitingPhase 1/2
- Massachusetts General Hospital, Boston
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
RecruitingPhase 3
- Tufts Medical Center ( Site 6052), Boston
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
RecruitingPhase 1
- Dana-Farber Cancer Institute, Boston
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RecruitingPhase 3
- Dana-Farber Cancer Institute, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RecruitingPhase 1
- Dana Farber Cancer Institute, Boston
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RecruitingPhase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RecruitingPhase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
Recruiting
- Dana-Farber Cancer Institute, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RecruitingPhase 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RecruitingPhase 1
- Dana Farber Cancer Institute, Boston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
RecruitingPhase 1/2
- Massachusetts General Hospital, Boston
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
RecruitingPhase 1
- Massachusetts General Brigham, Boston
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
RecruitingPhase 1
- Dana-Farber Cancer Institute, Boston
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Dana Farber Cancer Institute, Boston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
- Massachusetts General Hospital, Boston
ALPINE: Maintenance Letrozole/Abemaciclib
RecruitingPhase 2
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
- Dana Farber Cancer Institute, Boston
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RecruitingPhase 1/2
- Research Site, Boston
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RecruitingPhase 3
- Research Site, Boston
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RecruitingPhase 1/2
- Research Site, Boston
A Study of PHST001 in Advanced Solid Tumors
RecruitingPhase 1
- Dana Farber Cancer Institute, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
RecruitingPhase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber / Harvard Cancer Center, Boston
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
RecruitingPhase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute Brookline Avenue, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecruitingPhase 1/2
- Dana Farber Cancer Institute, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RecruitingPhase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
RecruitingPhase 1
- Dana-Farber Cancer Institute, Boston
Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
Recruiting
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
RecruitingPhase 1
- Mass General Cancer Center, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingPhase 1/2
- Dana-Farber Cancer Institute, Boston
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
RecruitingPhase 2
- Dana Farber Cancer Institute, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RecruitingPhase 1/2
- Massachusetts General Hospital, Boston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RecruitingPhase 1
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- Massachusetts General Hospital Cancer Center, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RecruitingPhase 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer
RecruitingPhase 2
- Massachusetts General Hospital Cancer Center, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome
RecruitingHealthy volunteers welcome
- Dana-Farber Cancer Institute, Boston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RecruitingPhase 1/2
- Massachusetts General Hospital, Boston
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
Recruiting
- Dana Farber Cancer Institute, Boston
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
RecruitingPhase 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
RecruitingPhase 1/2
- Dana Farber Cancer Institute, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RecruitingPhase 1/2
- Massachusetts General Hospital, Boston
Comprehensive Outcomes for After Cancer Health
RecruitingHealthy volunteers welcome
- Dana Farber Cancer Institute, Boston
Endometrial Cancer trials in other cities
- Houston, TX69 studies
- New York City, NY54 studies
- Arlington, VA41 studies
- Nashville, TN38 studies
- Los Angeles, CA35 studies
- St. Louis, MO29 studies
- Philadelphia, PA29 studies
- Oklahoma City, OK28 studies
- San Antonio, TX27 studies
- Queens, NY26 studies
- Dallas, TX25 studies
- Pittsburgh, PA24 studies
Other studies in Boston
- Breast Cancer110 studies
- Cancer (all types)90 studies
- Non-Small Cell Lung Cancer87 studies
- Lung Cancer63 studies
- Colorectal Cancer62 studies
- Ovarian Cancer62 studies
- Metastatic Cancer61 studies
- Prostate Cancer56 studies
- Depression50 studies
- Heart Failure46 studies
- Multiple Myeloma45 studies
- Acute Myeloid Leukemia44 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.